The Obesity-Diabetes Drugs Market is estimated to be valued at USD 59.9 billion in 2025 and is projected to reach USD 103.3 billion by 2035, registering a compound annual growth rate (CAGR) of 5.6% over the forecast period.

The Europe Diabetes Drugs Market Report is Segmented by Drug Class (Insulins [Basal/Long-acting and More], Oral Anti-Diabetics [Biguanides and More], Non-Insulin Injectable Drugs, Combination Drugs), Diabetes Type (Type-1 and Type-2), Rout of Administartion (Oral, Inhaled and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Introduction

Global Diabetes Drugs Market size is expected to be worth around USD 153.4 Billion by 2033, from USD 69.1 Billion in 2023, growing at a CAGR of 8.6% during the forecast period from 2024 to 2033. In 2023, North America led the market, achieving over 51.3% share with a revenue of US$ 35.4 Million.

Several factors are driving the growth of the diabetes drug market. A key factor is the rising prevalence of diabetes globally, especially type 2 diabetes. Data from the International Diabetes Federation indicates that the number of adults with diabetes is expected to increase from 537 million in 2021 to 783 million by 2045. Furthermore, advancements in diabetes medications, such as the introduction of GLP-1 receptor agonists and SGLT-2 inhibitors, offer effective alternatives to traditional therapies, enhancing market expansion.

Recent developments in the sector include the introduction of new drugs and formulations. For example, Glenmark Pharmaceuticals launched Lirafit, a biosimilar of the popular anti-diabetic drug Liraglutide, in India in January 2024. Additionally, companies like Akums Drugs and Pharmaceuticals have been developing novel combination therapies aimed at improving treatment effectiveness and adherence among the elderly with type 2 diabetes.

Despite these advancements, the market faces challenges such as the high costs associated with diabetes drug therapies, which pose significant barriers, particularly in less developed regions. Nonetheless, the ongoing focus on diabetes care, coupled with increasing awareness and substantial research and development investments by leading companies, are anticipated to maintain the market's growth trajectory. North America leads this market, propelled by high obesity rates and sedentary lifestyles, with the United States holding the largest share due to its significant demand for insulin and other diabetes medications.

Type 1 Diabetes Market valued at USD 16.97 Bn in 2025, is anticipated to reaching USD 26.22 Bn by 2032, with a steady annual growth rate of 6.4%.

The North America Diabetes Drugs Market Report is Segmented by Drug Class (Insulins [Biosimilar Insulin and More], Non-Insulin Injectable, Oral Anti-Diabetic and Combination Drugs), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Drug Origin (Branded and Generic/Biosimilar), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

The global diabetes care devices market is expected to reach USD 64.5 billion in 2024. The sales are expected to grow even higher and will be estimated at USD 117.7 billion in 2034 due to the rising diabetes population. The diabetes care devices market is anticipated to record a CAGR of 6.2% between 2024 and 2034.

Semi-annual Industry Update

Country-wise Insights

Category-wise Insights

The India diabetes market size was valued at INR 316.00 Billion in 2024, driven by high prevalence of diabetes cases across the region. The market is expected to grow at a CAGR of 16.00% during the forecast period of 2025-2034, to reach INR 1394.01 Billion by 2034.

The global pediatric diabetes therapeutic market is set to reach USD 1,633.8 million in 2024. Projections indicate that the sector is anticipated to elevate to USD 2,612.4 million by 2034. The industry stood at USD 1,540.2 million in 2023 and is anticipated to exhibit a Y-o-Y growth of 6.1% in 2024. Demand for pediatric diabetes therapeutics is slated to surge at a 4.8% CAGR.

Country-wise Insights

Category-wise Insights

The size of the Europe Diabetes Drugs market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 4.25% during the forecast period. Recent developments include: Feburary 2023: Forxiga (dapagliflozin) has been approved in the European Union to extend the indication for heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF), including HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF)., March 2022: Eli Lilly and Boehringer Ingelheim gained approval for heart failure treatment from the EU for sodium-glucose co-transporter-2-inhibitor (SGLT2-I) and Jardiance (empagliflozin). Previously Jardiance gained a label expansion for treating HF in the US.. Key drivers for this market are: Increased Prevalence of Short Bowel Syndrome and GI disorders such as volvulus, Inflammatory bowel disease (IBD), Crohn's disease (CD) etc., Rising Efforts in the Launch of Effective Treatments and Awareness Programs by Non-Profit Organizations. Potential restraints include: Lack of Availability of the Approved Drugs in Developing Countries, Lethal Adverse Complications like Colonic Cancer, Polyps along with Common Side Effects Associated with the Medication. Notable trends are: The Oral anti-diabetic drugs segment held the highest market share in the Europe Diabetes Drugs Market in the current year.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion, at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of diabetes, fueled by an increasing geriatric population. This demographic trend, coupled with the underdiagnosis of the condition, presents both opportunities and challenges for market participants. The large, untapped population of undiagnosed individuals represents a significant market opportunity for innovative diagnostic solutions. However, the low diagnosis rate also poses a challenge, as untreated diabetes can lead to severe health complications and increased healthcare costs. The geriatric population, with its higher susceptibility to diabetes, further exacerbates this challenge.
To capitalize on the market opportunities and navigate these challenges effectively, companies must focus on developing innovative diagnostic tools and effective patient education programs. By addressing the unmet needs in diabetes diagnosis and management, market participants can differentiate themselves and capture a larger share of this growing market.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in diabetes management, public health, and weight management. Pancreatic beta-cell destruction and the subsequent need for insulin therapy remain at the forefront of market dynamics. Diabetes burden is a significant concern, with diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy posing significant health risks. SGLT2 inhibitors have emerged as a promising treatment option, addressing both glycemic control and cardiovascular disease. Healthcare access and access to care are crucial factors shaping the market. Global health initiatives and healthcare costs are influencing the development of diabetes technology, including insulin delivery devices, glucose sensors, and remote monitoring.

Precision medicine, data analytics, and machine learning are transforming diabetes education and patient engagement. Lifestyle modifications, such as dietary changes and physical activity, remain essential components of diabetes management. Insulin resistance, insulin therapy, and HbA1c testing continue to be key areas of focus in the medical device industry. Ongoing research in areas like Genetic Testing, Stem Cell Therapy, and primary care physician engagement is further shaping the market. Health disparities, early detection, and glycemic control are critical public health concerns. Diabetes prevention and healthcare provider collaboration are essential to improving health outcomes. The market is continually unfolding, with ongoing drug development, clinical trials, and advancements in diabetes technology driving innovation.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

.

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a complex condition characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to elevated blood glucose levels. Metabolic syndrome, an autoimmune disease, and a precursor to type 2 diabetes, affects millions worldwide. The medical device industry is responding with innovative solutions, such as artificial pancreas systems and insulin delivery devices, to improve glycemic control and enhance quality of life. Artificial intelligence and machine learning are revolutionizing diabetes management by facilitating early detection, personalized treatment plans, and remote monitoring. Diabetes burden is significant, with complications including diabetic foot ulcers, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy.

Prevention and management involve lifestyle modifications, such as dietary changes and physical activity, as well as pharmacological interventions, including oral antidiabetic medications, insulin therapy, and newer classes like GLP-1 receptor a

Type 2 Diabetes Market valuation is estimated to reach USD 43.02 Bn in 2025 and is anticipated to grow to USD 73.31 Bn by 2032 with steady CAGR of 7.9%

The Diabetes Care Devices Market is Segmented by Management Devices (Insulin Pumps, Insulin Syringes, and More), Monitoring Devices (Self-Monitoring Blood Glucose and Continuous Glucose Monitoring), by Patient Type (Type-1 Diabetes, Type-2 Diabetes and More), by End User (Hospitals & Clinics, Home-Care Settings and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

The global gestational diabetes market is projected to exceed USD 19,811.32 Mn by 2032, advancing from USD 9,870.25 Mn in 2024, with an estimated growth of USD 10,592.57 Mn in 2025, at a CAGR of 9.1% from 2025 to 2032.

The global market for diabetes management apps is experiencing substantial growth, driven by the escalating prevalence of diabetes worldwide and the increasing adoption of smartphones and digital health technologies. These applications empower patients with tools for self-management, tracking glucose levels, diet, and physical activity, thereby improving health outcomes. The integration of advanced features like AI-driven insights, real-time coaching, and seamless connectivity with medical devices like continuous glucose monitors (CGMs) is further propelling market expansion. As healthcare systems shift towards preventative and patient-centric care models, these apps are becoming integral components of modern diabetes care. The market is characterized by intense competition, with a focus on user experience, clinical accuracy, and data security to build user trust and ensure long-term engagement.

Key strategic insights from our comprehensive analysis reveal:

  The Asia-Pacific region is emerging as the epicenter of growth, boasting the highest CAGR of 11.5%, driven by a large diabetic population and rapidly increasing smartphone penetration, with India leading the charge at a remarkable 13.3% CAGR.
  Integration with wearable technology and continuous glucose monitoring (CGM) systems is no longer a niche feature but a critical requirement for market competitiveness, offering users a holistic view of their health.
  Personalization through Artificial Intelligence (AI) and machine learning is a key differentiator, enabling apps to provide customized advice, predictive alerts, and tailored educational content, significantly enhancing user engagement and clinical effectiveness.


Global Market Overview & Dynamics of Diabetes Management Apps Market Analysis
The global diabetes management apps market is on a significant upward trajectory, fueled by a convergence of technological advancement and a growing global health crisis. With the rising number of individuals diagnosed with diabetes, there is an increasing demand for accessible and effective tools for daily management. These apps provide a platform for continuous monitoring, data logging, and lifestyle management, bridging the gap between patient visits. The market's momentum is sustained by continuous innovation, supportive healthcare policies promoting digital health, and growing patient awareness regarding the benefits of self-care technologies.

Global Diabetes Management Apps Market Drivers

  Increasing Prevalence of Diabetes: The surging number of people with type 1 and type 2 diabetes globally is the primary driver, creating a massive user base for management and monitoring solutions.
  High Smartphone Penetration: The widespread availability and adoption of smartphones provide an accessible platform for deploying digital health applications, making diabetes management more convenient.
  Growing Focus on Patient-Centric Healthcare: A paradigm shift towards value-based and preventative care encourages patient involvement in their own health, positioning these apps as essential self-management tools.


Global Diabetes Management Apps Market Trends

  Integration of AI and Big Data: Companies are leveraging artificial intelligence to offer personalized insights, predict hypoglycemic/hyperglycemic events, and provide automated coaching, enhancing the value proposition.
  Seamless Wearable and CGM Device Connectivity: The trend towards interoperability with wearables (like smartwatches) and medical devices (like CGMs and smart insulin pens) allows for automatic, real-time data syncing and a more comprehensive health overview.
  Gamification for Enhanced User Engagement: Incorporating game-like elements, rewards, and challenges into apps is a growing trend to improve user adherence, motivation, and long-term retention.


Global Diabetes Management Apps Market Restraints

  Data Privacy and Security Concerns: The handling of sensitive personal health information raises significant concerns among users and regulators, necessitating robust security measures and compliance with regulations like HIPAA and GDPR.
  Lack of Reimbursement and Clear Regulatory Pathways: In many countries, the absence of clear reimbursement policies for digital therapeutics and complex regulatory approval processes can hinder market growth.
  Issues with Accuracy and User Adherence: Concerns over the clinical accuracy of some apps and the challenge of maintainin...

The China diabetes market was valued at USD 4.73 Billion in 2024 and is expected to grow at a CAGR of 9.50%, reaching USD 11.72 Billion by 2034. The market growth is driven by increasing urbanization, growing health awareness, and a rising aging population with sedentary lifestyles across the region. Expanding access to digital health platforms and wearable glucose monitoring devices is boosting patient engagement. Government initiatives for early diagnosis and disease management, along with technological advancements in insulin delivery, are projected to support market growth over the forecast period.

Key Market Trends and Insights

• By diabetes type, the type 2 segment held approximately 79% in 2024 during the historical period.
• Based on drugs, the non-insulin injectable segment held around 35% during the historical period.
• The intravenous segment dominated the market by route of administration with nearly 40% during the historical period.

Market Size and Forecast

• Market Size (2024): USD 4.73 Billion
• Projected Market Size (2034): USD 11.72 Billion
• CAGR (2025-2034): 9.50%

Diabetes Care Market holds a forecasted revenue of USD 34.51 Bn in 2025 and is likely to cross USD 62.73 Bn by 2032. with a steady annual growth rate of 8.9%.

According to Cognitive Market Research, the global Type 2 Diabetes Mellitus Therapeutic market size was USD 19514.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 8.80% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 7805.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 5854.35 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 4488.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.8% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 975.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 390.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
The SGLT2 inhibitors category is the fastest growing segment of the Type 2 Diabetes Mellitus Therapeutic industry

Market Dynamics of Type 2 Diabetes Mellitus Therapeutic Market

Key Drivers for Type 2 Diabetes Mellitus Therapeutic Market

Growing Prevalence of Type 2 Diabetes to Boost Market Growth

The rising incidence of type 2 diabetes globally is a significant driver for the therapeutic market. With lifestyle changes such as poor diet, lack of exercise, and increasing rates of obesity, the number of people diagnosed with type 2 diabetes has surged in recent years. The World Health Organization (WHO) and other health bodies have noted a steady increase in diabetes cases, particularly in developing nations, due to urbanization and changing dietary habits. As the disease burden grows, the demand for effective therapies, including oral medications, insulin, and emerging treatments like GLP-1 receptor agonists, has intensified. Pharmaceutical companies are responding to this demand by advancing research, improving drug efficacy, and focusing on developing treatments that address underlying risk factors, such as insulin resistance. This expanding patient pool drives market growth, making it a lucrative sector for therapeutic advancements. For instance, Pfizer Inc. announced its commitment to advancing a late-stage oral glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate into further clinical development. This innovative therapy aims to address obesity and diabetes in adults, reflecting Pfizer's intentions to expand treatment options for these prevalent conditions

Advancements in Diabetes Management Technology to Drive Market Growth

Advancements in diabetes management technology, such as continuous glucose monitoring (CGM) systems and insulin pumps, are driving the type 2 diabetes therapeutic market. These technologies have revolutionized how patients manage their blood glucose levels and improve treatment outcomes. With more accurate monitoring and real-time feedback, patients can better control their diabetes and avoid complications. Furthermore, digital health tools like mobile apps and telemedicine platforms have become integral parts of diabetes management, making treatment more accessible and efficient. As these technologies evolve, they create new opportunities for targeted therapeutic solutions, including combination therapies that integrate medication with digital health solutions. This innovation not only improves patient adherence to prescribed regimens but also boosts demand for more personalized, effective treatment options, contributing to the overall growth of the therapeutic market.

Restraint Factor for the Type 2 Diabetes Mellitus Therapeutic Market

High Treatment Costs and Accessibility Will Limit Market Growth

One of the major restraining factors for the Type 2 diabetes mellitus therapeutic market is the high cost of treatment, particularly with newer medications and advanced insulin therapies. Innovative treatments like SGLT2 inhibitors, GLP-1 receptor agonists, and insulin pumps can be expensive, leading to financial burdens for patients, especially in low-income regions. Additionally, healthcare systems with limited budgets may prioritize other medical needs, further hindering accessibility....

The US diabetes drugs and devices market is booming, projected to surpass $82 billion by 2033, driven by rising diabetes prevalence and innovative treatment advancements. Explore market trends, key players (Novo Nordisk, Medtronic, Abbott), and regional insights in this comprehensive analysis. Recent developments include: June 2023: The initial allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells, Lantidra, has been sanctioned by the U.S. Food and Drug Administration for the management of type 1 diabetes. Lantidra is specifically authorized for adults with type 1 diabetes who are incapable of achieving target glycated hemoglobin (average blood glucose levels) due to recurrent episodes of severe hypoglycemia (low blood sugar) despite intensive diabetes management and education., January 2023: Bexagliflozin (Brenzavvy, TheracosBio) has been granted approval by the US Food and Drug Administration (FDA) for the management of type 2 diabetes in adults. This oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, taken once daily at a dosage of 20 mg, is recommended as a supplementary treatment alongside diet and exercise to enhance glycemic control specifically for individuals with type 2 diabetes, excluding those with type 1 diabetes.. Notable trends are: Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period.

The global diabetes care market is projected to be valued at $150 billion in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of 5.4%, reaching approximately $240 billion by 2034.

[213+ Pages Report] The global Diabetes Management Market size is expected to grow from USD 18.23 billion in 2022 to USD 36.02 billion by 2030, at a CAGR of 8.87% from 2023-2030